JP2013518061A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518061A5
JP2013518061A5 JP2012550265A JP2012550265A JP2013518061A5 JP 2013518061 A5 JP2013518061 A5 JP 2013518061A5 JP 2012550265 A JP2012550265 A JP 2012550265A JP 2012550265 A JP2012550265 A JP 2012550265A JP 2013518061 A5 JP2013518061 A5 JP 2013518061A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
phenylaminoethane
hydrazide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012550265A
Other languages
English (en)
Japanese (ja)
Other versions
JP5788907B2 (ja
JP2013518061A (ja
Filing date
Publication date
Priority claimed from AT0012210A external-priority patent/AT509045B1/de
Application filed filed Critical
Publication of JP2013518061A publication Critical patent/JP2013518061A/ja
Publication of JP2013518061A5 publication Critical patent/JP2013518061A5/ja
Application granted granted Critical
Publication of JP5788907B2 publication Critical patent/JP5788907B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012550265A 2010-01-29 2011-01-28 疾患の治療に使用される化合物 Expired - Fee Related JP5788907B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0012210A AT509045B1 (de) 2010-01-29 2010-01-29 Verbindungen zur behandlung von asthma bronchiale
ATA122/2010 2010-01-29
PCT/AT2011/000050 WO2011091461A1 (de) 2010-01-29 2011-01-28 Verbindungen zur verwendung bei der behandlung von erkrankungen

Publications (3)

Publication Number Publication Date
JP2013518061A JP2013518061A (ja) 2013-05-20
JP2013518061A5 true JP2013518061A5 (enExample) 2014-02-13
JP5788907B2 JP5788907B2 (ja) 2015-10-07

Family

ID=43707937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012550265A Expired - Fee Related JP5788907B2 (ja) 2010-01-29 2011-01-28 疾患の治療に使用される化合物

Country Status (12)

Country Link
US (1) US20130065962A1 (enExample)
EP (2) EP2965755A1 (enExample)
JP (1) JP5788907B2 (enExample)
KR (1) KR20120128644A (enExample)
CN (2) CN102858329B (enExample)
AT (1) AT509045B1 (enExample)
AU (1) AU2011208939B2 (enExample)
BR (1) BR112012018772A2 (enExample)
CA (1) CA2788326A1 (enExample)
MX (1) MX2012008815A (enExample)
SG (1) SG182786A1 (enExample)
WO (1) WO2011091461A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150237857A1 (en) * 2012-08-10 2015-08-27 Mcmaster University Antibacterial inhibitors
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
PL3203998T3 (pl) * 2014-10-10 2021-09-27 Liminal Biosciences Limited Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia cukrzycy
EP3323428A1 (en) * 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selective c-flip inhibitors as anticancer agents
AU2022251175A1 (en) * 2021-03-31 2023-09-21 Chevron Oronite Company Llc Compositions for mitigating low speed pre-ignition events

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082846A (en) 1976-11-18 1978-04-04 University Of Utah Method for treating psoriasis
EP0323590A3 (en) 1987-12-24 1990-05-02 Ono Pharmaceutical Co., Ltd. Carbazoyl derivatives
JPH02753A (ja) * 1987-12-24 1990-01-05 Ono Pharmaceut Co Ltd カルバゾイル誘導体、それらの製造方法およびそれらを有効成分として含有するメイラード反応阻害剤
WO1992017065A2 (en) 1991-04-01 1992-10-15 Duke University Method of inhibiting fibrosis
US5324747A (en) * 1992-07-15 1994-06-28 Hoffmann-La Roche Inc. N-substituted anilines, inhibitors of phospholipases A2
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US6197743B1 (en) * 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
US5741926A (en) * 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
WO1999040883A2 (en) * 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
CN1148176C (zh) * 1998-09-15 2004-05-05 韩国生命工学研究院 用于预防或治疗与血脂水平升高相关的疾病的含有肉桂酸衍生物的组合物
AU2004242565A1 (en) * 1999-01-12 2005-01-27 Kenneth Blum Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
ATE246177T1 (de) 1999-05-28 2003-08-15 Cheil Jedang Corp Katecholhydrazon-derivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten
IT1313567B1 (it) * 1999-07-27 2002-09-09 Zambon Spa Uso della n-acetil-cisteina per la preparazione di composizionifarmaceutiche topiche per il trattamento di patologie allergiche delle
US6444829B1 (en) 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
CA2481995A1 (en) 2002-04-08 2003-10-16 Torrent Pharmaceuticals Ltd. Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
US7741352B2 (en) 2003-03-11 2010-06-22 Neurosearch A/S KCNQ channel modulating compounds and their pharmaceutical use
WO2005085185A1 (en) 2004-03-03 2005-09-15 Smithkline Beecham Corporation Aniline derivatives as selective androgen receptor modulators
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
CN1686297A (zh) * 2005-04-07 2005-10-26 甘肃圣达医药科技有限责任公司 一种止咳平喘药物及其制备方法
CU23431B6 (es) * 2005-05-12 2009-10-16 Ct Ingenieria Genetica Biotech Método para la inhibición de la proliferación de células tumorales y el tratamiento del cáncer
WO2007026215A1 (en) 2005-08-29 2007-03-08 Glenmark Pharmaceuticals S.A. Pyrazole derivatives as cannabinoid receptor ligands, pharmaceutical compositions containing? them, and processes for their preparation
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
CA2974246C (en) * 2006-09-01 2020-02-25 Senhwa Biosciences, Inc. Tricyclic heteroaryl compounds and their use as protein modulators
SG179437A1 (en) 2007-03-30 2012-04-27 Sanofi Aventis Pyrimidine hydrazide compounds as pgds inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
PT2427416E (pt) * 2009-05-04 2016-06-15 Prometic Pharma Smt Ltd Compostos aromáticos substituídos e seus usos farmacêuticos

Similar Documents

Publication Publication Date Title
JP2023002662A5 (enExample)
JP2016534063A5 (enExample)
JP2009514874A5 (enExample)
JP2010518122A5 (enExample)
JP2010077141A5 (enExample)
JP2012502037A5 (enExample)
JP2013542247A5 (enExample)
JP2011201907A5 (enExample)
JP2018507914A5 (enExample)
JP2016534153A5 (enExample)
JP2015057436A5 (enExample)
JP2014505107A5 (enExample)
JP2012520866A5 (enExample)
JP2009102342A5 (enExample)
JP2013534248A5 (enExample)
JP2013518107A5 (enExample)
JP2013520405A5 (enExample)
JP2006182786A5 (enExample)
JP2014500861A5 (enExample)
JP2017526716A5 (enExample)
JP2015510916A5 (enExample)
JP2010521417A5 (enExample)
JP2012255002A5 (enExample)
US10016397B2 (en) Selective AT2 receptor agonists for use in treatment of cachexia
JP2017222722A5 (enExample)